Immunotherapy combo may delay progression in advanced bladder cancer

NCT ID NCT05219435

Completed Disease control Sponsor: Spanish Oncology Genito-Urinary Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) could help keep advanced bladder cancer from growing after initial chemotherapy. It involved 25 adults whose cancer had not worsened after first-line chemo. The goal was to see if this maintenance treatment could delay disease progression and improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CANCER

Contacts and locations

Locations

Complejo asistencial universitario de Salamanca

Salamanca, Castille and León, 37007, Spain
Hospital Clínic de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Clínico Universitario de Santiago de Compostela

Santiago de Compostela, Galicia, 15706, Spain
Hospital Clínico Universitario de Zaragoza

Zaragoza, Aragon, 50009, Spain
Hospital Universitario 12 de Octubre

Madrid, Madrid, 28041, Spain
Hospital Universitario Central de Asturias

Oviedo, Principality of Asturias, 33011, Spain
Hospital Universitario Juan Ramón Jiménez

Huelva, Andalusia, 21005, Spain
Hospital Universitario Ramón y Cajal

Madrid, Madrid, 28034, Spain
Hospital Universitario Son Espases

Palma de Mallorca, Balearic Islands, 07120, Spain
Hospital Universitario Virgen de la Macarena

Seville, Andalusia, 41009, Spain
Hospital Universitario de Toledo

Toledo, Castille-La Mancha, 45004, Spain
Hospital Universitario de la Ribera

Alzira, Valencia, 46600, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.